JPS5732225A - Human plasmatic crystalline alpha2-macroglobulin and its preparation - Google Patents
Human plasmatic crystalline alpha2-macroglobulin and its preparationInfo
- Publication number
- JPS5732225A JPS5732225A JP10868180A JP10868180A JPS5732225A JP S5732225 A JPS5732225 A JP S5732225A JP 10868180 A JP10868180 A JP 10868180A JP 10868180 A JP10868180 A JP 10868180A JP S5732225 A JPS5732225 A JP S5732225A
- Authority
- JP
- Japan
- Prior art keywords
- macroglobulin
- human
- crystalline
- plasmatic
- protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
NEW MATERIAL:A human plasmatic crystalline α2-macroglobulin. Molecular weight : 7.6×105 (measured by the gel filtration method with Sepharose 6B). Absorbance : E280 1%nm,1cm 8.3(25°C, 0.05M phosphoric acid buffer solution, pH7.0). Isoelectric point: pH5.3.
USE: A protease inhibitor, having improved storage stability because of the crystallinity, and capable of inhibiting the abnormal increase in protease activity due to the inflammation or pancreatitis of a living body and preventing the decomposition of peptide hormone or enzyme, etc. by the contaminant protease on purification by the addition thereto.
PROCESS: An α2-macroglobulin franction of a human plasma is concentrated by the ultrafiltration to give a human plasmatic crystalline α2-macroglobulin. The raw material α2-macroglobulin is obtained by separating and purifying a human dried plasma with the gel filtration and the colum chromatography.
COPYRIGHT: (C)1982,JPO&Japio
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10868180A JPS5732225A (en) | 1980-08-06 | 1980-08-06 | Human plasmatic crystalline alpha2-macroglobulin and its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10868180A JPS5732225A (en) | 1980-08-06 | 1980-08-06 | Human plasmatic crystalline alpha2-macroglobulin and its preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS5732225A true JPS5732225A (en) | 1982-02-20 |
Family
ID=14490964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10868180A Pending JPS5732225A (en) | 1980-08-06 | 1980-08-06 | Human plasmatic crystalline alpha2-macroglobulin and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5732225A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2827882A4 (en) * | 2012-02-21 | 2016-01-27 | Cytonics Corp | Systems, compositions, and methods for transplantation |
-
1980
- 1980-08-06 JP JP10868180A patent/JPS5732225A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2827882A4 (en) * | 2012-02-21 | 2016-01-27 | Cytonics Corp | Systems, compositions, and methods for transplantation |
AU2013222414B2 (en) * | 2012-02-21 | 2018-02-15 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
US10265388B2 (en) | 2012-02-21 | 2019-04-23 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
US10940189B2 (en) | 2012-02-21 | 2021-03-09 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
US11040092B2 (en) | 2012-02-21 | 2021-06-22 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO175716C (en) | Analogous Process for Preparation of Therapeutically Active, Total and Partial Hyaluronic Acid Esters | |
JPS6434923A (en) | Aerosolization of proteinaceous remedy | |
EP0132732A3 (en) | Homologues from aprotinine whose lys 15 amino acid is substituted by other amino acids, process for their preparation and their use as medicaments | |
Zuber | Purification and properties of a new carboxypeptidase from citrus fruit | |
PT87652A (en) | PROCESS FOR THE PREPARATION OF PEPTIDE BOBONIC ACID INHIBITORS OF TRYPSIN-LIKE PROTEASES | |
NZ302984A (en) | Multifunctional enzyme having N-terminal sequence IVGGXEVTPHAYPWQVGLFIDDMYF, where X is any amino acid | |
JPS6443152A (en) | Stabilized chewing gum product and its production | |
CA1188218A (en) | Purified antineoplaston fractions and methods of treating neoplastic disease | |
CA2053242C (en) | Protease inhibitor | |
Janoff et al. | Further studies on elastase-like esterases in human leukocyte granules | |
EP0225020A3 (en) | Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of vip | |
NZ510390A (en) | TNF-alpha converting enzyme | |
FI871087A0 (en) | Process for the preparation of therapeutically active 1,2,3,4-tetrahydro-3-carbamoyl-2-thioxo / oxo-5-pyrimidinecarboxylic acid derivatives | |
CA2105282A1 (en) | Preparation of factor ix | |
Yamada et al. | The effects of protease inhibitors on histidine decarboxylase activities and assay of enzyme in various rat tissues | |
AU5232886A (en) | Serine protease inhibitors and methods for isolation of same | |
PL260757A1 (en) | Procedure for the purification and production of /5r/ /z/-6-/1-methyl-1,2,3-triazole-4-ilomethylene/ penemo-3-carboxylic acid | |
JPS5732225A (en) | Human plasmatic crystalline alpha2-macroglobulin and its preparation | |
EP0642348A4 (en) | Antibiotic cryptdin peptides and methods of their use. | |
JPS6456699A (en) | Method for obtaining alpha 1-antitrypsin concentrate from human plasma and its utilization as drug | |
AU4827085A (en) | Method for treatment of antidiuresis employing serine derivatives | |
JPS649938A (en) | Oral ingestive composition | |
NO164243C (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTICALLY ACTIVE 16,17-ACETALS-SUBSTITUTED PREGNAN-21-ACETIC ACID DERIVATIVES | |
AU576750B2 (en) | Method of determining antigenically active amino acid sequences | |
EP0261088A3 (en) | Process for the production of heparanlysopeptide sulphate, the product thus obtained and its therapeutic use |